ECP 2022 Final Programme

Poster Sessions a Sunday 81 ECP 2022 Basel Sunday, 4 Sept PS-01 013 Comparison of HercepTest™ mAb pharmDx (Dako Omnis) (GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer Josef Rüschoff, Germany M. Friedrich, I. Nagelmeier, M. Kirchner, L. Andresen, K. Salomon, B. Portier, S. Sredni, H. Schildhaus, B. Jasani, M. Grzelinski, G. Viale 014 Phosphohistone H3 versus mitotic count in breast cancer grading: a single institution study Nada Mansouri, Tunisia F. Gargouri, M. Ben Thayer, K. Tlili, R. Aouadi, I. Msakni, B. Laabidi 015 Immune checkpoint genes expression in breast carcinoma: correlation with clinicopathological features and patients survival Yoel Genaro Montoyo Pujol, Spain M. García-Escolano, T. Martin-Bayon, S. Delgado-García, H. Ballester, J. Ponce, E. Castellón-Molla, J. Sempere-Ortells, F. Aranda López, G. Peiró 016 The malignancy of benignancy. The malignant consequences of benign breast tumours. Is the onus on pathologists? Post-pregnancy associated infarcted fibroadenoma, a rapidly growing benign phyllodes tumour, a benign phyllodes tumour in an adolescent girl Silvana Di Palma, United Kingdom A. Gamage, P. Partlett, F. Pakzad, E. Rakha, E. Clayton 018 Breast interstitium or “Hartveit's Labyrinth”: morphology and relationship to disease processes Stella Gordin, USA B. Belovarac, A. Serrano, L. Chiriboga, B. Zeck, F. Darvishian, D. Nimeh, U. Ozerdem, S. Badve, R. Wells, N. Theise 019 The effect of neoadjuvant chemotherapy on histologic grade and hormone receptor status in HER2/Neu-negative Luminal-B tumours of the breast Ozgur Can Eren, Turkey S. Horoz, N. Arı, G. Menetlioglu, H. Kaya 020 Morphological and crystalchemical features of breast cancer microcalcificates Olena Kolomiiets, Ukraine A. Piddubnyi, S. Danilchenko, R. Moskalenko 021 HER-2 ISH: do we need to count? Simona Costache, Romania A. Baltan, A. Jurkiewicz, M. Porter, K. Billingham, H. Haynes, A. Chefani, S. Wedden, M. Sajin, C. D’Arrigo 022 Pathological features of CT-guided bone lesion biopsy specimens in breast cancer patients Martina Abramovic, Croatia L. Korša, L. Grbanović, M. Čavka, I. Švagelj, M. Prutki, Z. Marušić 023 Luminal breast cancer subtypes and associated prognostic factors: a popula- tion-based study from Osijek, Croatia Darija Damjanovic, Croatia J. Rajc, K. Marjanović, R. Gudelj, M. Bakula, R. Alaghehbandan 024 Ki67 proliferative index in patients with early breast cancer and its association with clinicopathological factors Darija Damjanovic, Croatia J. Rajc, E. Matuzalem Marinović, B. Dumenčić, R. Gudelj, M. Bakula, R. Alaghehbandan 025 To determine the accuracy of axillary staging using ultrasound-guided fine-needle aspiration cytology in breast cancer patients: a single institutional experience Ibrahim Aloglu, Turkey M. Doğan, S. Aydın Aksu, F. Aker